Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2005 Apr 15;15(8):2129-34.

Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic properties.

Author information

1
Department of Medicinal Chemistry, Merck Research Laboratories, RY800-206, PO Box 2000, Rahway, NJ 07065, USA. dooseop_kim@merck.com <dooseop_kim@merck.com>

Abstract

A series of 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists containing a variety of fused heterocycles at the 4-position of the piperidine side chain has been discovered, which are orally bioavailable with potent anti-HIV activity.

PMID:
15808483
DOI:
10.1016/j.bmcl.2005.02.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center